Medically induced hypoglycemia: focus on medications not included in the group of antihyperglycemic medications

Cover Page

Cite item

Full Text

Abstract

Recently, doctors face the problem of patients with hypoglycemia conditions caused by the use of drugs that are not drugs for the treatment of diabetes. This is due to the increase in the number of multimorbid diseases in people of older age groups and, consequently, an increase in the number of drugs used simultaneously (polypharmacy). Hypoglycemia can complicate the course of concomitant diseases, contributes to the occurrence of arrhythmias, increases the risk of cardiovascular events, cognitive impairment, including dementia, increases the frequency and duration of episodes of myocardial ischemia. Risk factors for the development of drug-induced hypoglycemia include: elderly and senile age; reduced glomerular filtration rate, liver failure (reduced gluconeogenesis), reduced food consumption (insufficient glucose consumption); excessive alcohol consumption (reduced gluconeogenesis, insufficient food intake); simultaneous intake of several drugs that can lead to hypoglycemia. The most frequently drug-induced hypoglycemia develops against the background of the use of quinolones, pentamidine, quinine, β-blockers, angiotensin-converting enzyme inhibitors and insulin-like growth factor. The main vehicle to prevent drug-induced hypoglycemia is to stop its use and/or replace it with another drug that does not have this side effect. If it is impossible to completely abandon the drug, it is necessary to minimize the risk of hypoglycemia in the following ways: use long-term administration of the same concentration of the drug (if possible, prolonged forms), reduce the dose of the drug (use the lowest possible effective doses), control the concentration of glucose in the blood.

About the authors

Olga D. Ostroumova

Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University; A.I.Yevdokimov Moscow State University of Medicine and Dentistry

Email: ostroumova.olga@mail.ru
D. Sci. (Med.), Full Prof. Moscow, Russia

Elizaveta S. Akimova

A.I.Yevdokimov Moscow State University of Medicine and Dentistry

Email: akimova.liza.96@gmail.com
Student Moscow, Russia

Aleksei I. Kochetkov

Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University

Cand. Sci. (Med.) Moscow, Russia

Anton P. Pereverzev

Russian Clinical and Research Center of Gerontology - Pirogov Russian National Research Medical University

Cand. Sci. (Med.) Moscow, Russia

References

  1. Дедов И.И., Шестакова М.В., Викулова О.К. и др. Сахарный диабет в Российской Федерации: распространенность, заболеваемость, смертность, параметры углеводного обмена и структура сахароснижающей терапии по данным Федерального регистра сахарного диабета, статус 2017 г. Сахарный диабет. 2018; 3 (21): 144-59. doi: 10.14341/DM9686
  2. Сычев Д.А. Полипрагмазия в клинической практике: проблема и решения. Учебное пособие для врачей. СПб., 2016.
  3. Vue M.H, Setter S.M. Drug-Induced Glucose Alterations Part 1: Drug-Induced Hypoglycemia. Diabetes Spectrum 2011; 24 (3): 171-7. DOI: 10.2337
  4. Pandit M, Burke J, Gustafson A et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993; 7: 529-39.
  5. Дедов И.И., Шестакова М.В., Майоров А.Ю. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 8-й выпуск. Сахарный диабет. 2017; 20 (1S): 1-121.
  6. Helms K, Kelley K. Drug-Induced Hypoglycemia, Hypoglycemia - Causes and Occurrences [online]. 2011; р. 113-30. http://cdn.intechopen.com/pdfswm/21469.pdf
  7. Zammit N.N, Frier B.M. Hypoglycemia in type 2 diabetes. Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28 (12): 2948-61.
  8. Murad M, Coto-Yglesias F, Wang A et al. Drug-induced hypoglycemia: a systematic review. J Clin Endocrinol Metab 2009; 94 (3): 741-5. DOI: 10,1210
  9. Seltzer H.S. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-1833.
  10. Ioannidis J.P, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001; 285: 437-4434.
  11. База данных неблагоприятных побочных реакций ВОЗ VigiBase. http://www.vigiaccess.org (Дата обращения: 17.12.2018).
  12. Ferriere M, Lachkar H, Richard J.L et al. Captopril and insulin sensitivity [letter]. Ann Intern Med 1985; 102: 134.
  13. White J. The contribution of medications to hypoglycemia unawareness. Diabetes Spectrum 2007; 20 (2): 77-80.
  14. White J.R, Campbell R.K. Dangerous and common drug interactions in patients with diabetes mellitus. Endocrinol Metab Clin North Am 2000; 29: 789-802.
  15. White J.R, Campbell R.K. Drug-drug and drug-disease interactions and diabetes. Diabetes Educ 1995; 21: 283-9.
  16. Product Information: InnoPran XL oral capsules, propranolol hydrochloride oral capsules. GlaxoSmithKline 2010.
  17. Ma R.C.W, Kong A.P.S, Chan N et al. Drug-induced endocrine and metabolic disorders. Drug Saf 2007; 30: 215-45.
  18. Thomson Reuters Healthcare: Micromedex Healthcare Series. Greenwood Village, Colo., Thomson Reuters Healthcare, 2011. 11.12.2018. http://www.micromedex.com/products/hcs
  19. Product Information: Pentam 300 IV, IM injection, pentamidine isethionate IV, IM injection. American Pharmaceutical Partners 2008.
  20. Product Information: Nebupent inhalation solution, pentamidine isethionate inhalation solution. American Pharmaceutical Partners 2018.
  21. Cryer P.E, Axelrod L, Grossman A.B et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2009; 94: 709-28.
  22. Maeda N, Tamagawa T, Niki I et al. Increase in insulin release by rat pancreatic islets by quinolone antibiotics. Br J Pharmacol 1996; 117: 372-6.
  23. Frothingham R. Glucose homeostasis abnormalities associated with use of gatifloxacin. Clin Infect Dis 2005; 41(9): 1269-76.
  24. Gajjar D, LaCreta F, Kollia G et al. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy 2000; 20 (6): 76-86.
  25. Park-Wyllie L, Juurlink D, Kopp A et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006; 354 (25): 1352-61.
  26. Product Information: Tequin oral tablets, injection, gatifloxacin oral tablets, injection. Bristol-Myers Squibb Company, 2011.
  27. Greenberg A.L, Decerbo M, Fan J. Gatifloxacin therapy associated with hypogly-cemia. Clin Infect Dis 2005; 40: 1210-1.
  28. Goldfine A.B, Fonseca V, Jablonski K.A et al. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 2005; 152: 346-57.
  29. Hundal R.S, Petersen K.F, Mayerson A.B et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6.
  30. Product Information: Indocin intravenous injection, indomethacin intravenous injection. Lundbeck Inc, 2010.
  31. Hosono S, Ohno T, Kimoto H et al. Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus. Pediatr Int 1999; 41 (5): 525-8.
  32. Product Information: Qualaquin oral capsules, quinine sulfate oral capsules. AR Scientific Inc, 2010.
  33. Field J.B, Williams H.E, Mortimore G.E. Studies on the mechanism of ethanol-induced hypoglycemia. J Clin Invest 1962; 42 (4): 497-506.
  34. Weathermon R, Crabb D.W. Alcohol and medication interactions. Alcohol Res Health 1999; 23 (1): 40-54.
  35. Cryer P.E, Davis S.N, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26 (3): 1902-12.

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies